Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Cholangiocarcinoma|Chondrosarcoma|Glioma|Any Solid Tumor
Interventions: DRUG: LY3410738|DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Durvalumab
Sponsor: Eli Lilly and Company
Collaborators: Loxo Oncology, Inc.